Immunoediting Dynamics in Glioblastoma: Implications for Immunotherapy Approaches

• Published in: Cancer control Vol. 31; p. 10732748241290067
• Main Authors: Amin, Tasbir, Hossain, Amana, Jerin, Nusrat, Mahmud, Imteaz, Rahman, Md Ahasanur, Rafiqul Islam, S M, Islam, S M Bakhtiar Ul
• Format: Journal Article
• Language: English
• Published: United States SAGE Publications 01.01.2024; SAGE Publishing
• Subjects: Brain Neoplasms - immunology; Brain Neoplasms - therapy; Glioblastoma - immunology; Glioblastoma - therapy; Humans; Immunotherapy - methods; Review; Tumor Escape - immunology; Tumor Microenvironment - immunology; glioblastoma; tumor microenvironment; chimeric antigen receptor-T; immunotherapy; immunoediting
• ISSN: 1073-2748; 1526-2359; 1526-2359
• DOI: 10.1177/10732748241290067

Glioblastoma is an aggressive primary brain tumor that poses many therapeutic difficulties because of the high rate of proliferation, genetic variability, and its immunosuppressive microenvironment. The theory of cancer immunoediting, which includes the phases of elimination, equilibrium, and escape, offers a paradigm for comprehending interactions between the immune system and glioblastoma. Immunoediting indicates the process by which immune cells initially suppress tumor development, but thereafter select for immune-resistant versions leading to tumor escape and progression. The tumor microenvironment (TME) in glioblastoma is particularly immunosuppressive, with regulatory T cells and myeloid-derived suppressor cells being involved in immune escape. To achieve an efficient immunotherapy for glioblastoma, it is crucial to understand these mechanisms within the TME. Existing immunotherapeutic modalities such as chimeric antigen receptor T cells and immune checkpoint inhibitors have been met with some level of resistance because of the heterogeneous nature of the immune response to glioblastoma. Solving these issues is critical to develop novel strategies capable of modulating the TME and re-establishing normal immune monitoring. Further studies should be conducted to identify the molecular and cellular events that underlie the immunosuppressive tumor microenvironment in glioblastoma. Comprehending and modifying the stages of immunoediting in glioblastoma could facilitate the development of more potent and long-lasting therapies.